PSA BOUNCE AND BIOCHEMICAL FAILURE AFTER BRACHYTHERAPY FOR PROSTATE CANCER: A STUDY OF 820 PATIENTS WITH A MINIMUM OF 3 YEARS OF FOLLOW-UP

Basit Öğe Kaydı
dc.authoridReddy, Chandana/0000-0002-3832-8744
dc.contributor.authorCaloglu, Murat
dc.contributor.authorCiezki, Jay P.
dc.contributor.authorReddy, Chandana A.
dc.contributor.authorAngermeier, Kenneth
dc.contributor.authorUlchaker, James
dc.contributor.authorChehade, Nabil
dc.contributor.authorAltman, Andrew
dc.date.accessioned2024-06-12T10:54:36Z
dc.date.available2024-06-12T10:54:36Z
dc.date.issued2011
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To determine clinical or dosimetric factors associated with a prostate-specific antigen (PSA) bounce, as well as an association between a PSA bounce and biochemical relapse-free survival (bRFS), in patients treated with iodine-125 brachytherapy. Methods and Materials: A variety of clinical and treatment factors were examined in 820 patients who had a minimum of 3 years of PSA follow-up with T1-T2cN0M0 prostate cancer. Four different PSA threshold values were used for defining a PSA bounce: a PSA rise of >= 0.2, >= 0.4, >= 0.6, and >= 0.8 ng/mL. Results: A PSA bounce of >= 0.2, >= 0.4, >= 0.6, and >= 0.8 ng/mL was noted in 247 patients (30.1%), 161 (19.6%), 105 (12.8%), and 78 (9.5%), respectively. The median time to the first PSA rise was 17.4, 16.25, 16.23, and 15.71 months, respectively, vs. 34.35 months for a biochemical failure (p < 0.0001). A PSA rise of >= 0.2 ng/mL was the only definition for which there was a significant difference in bRFS between bounce and non-bounce patients. The 5-year bRFS rate of patients having a PSA bounce of >= 0.2 was 97.7% vs. 91% for those who did not have a PSA bounce (p = 0.0011). On univariate analysis for biochemical failure, age, risk group, and PSAs per year had a statistically significant correlation with PSA bounce of >= 0.2 ng/mL. On multivariate analysis, age and PSAs per year remained statistically significant (p < 0.0001 and p = 0.0456, respectively). Conclusions: A bounce definition of a rise >= 0.2 ng/mL is a reliable definition among several other definitions. The time to first PSA rise is the most valuable factor for distinguishing between a bounce and biochemical failure. (C) 2011 Elsevier Inc.en_US
dc.identifier.doi10.1016/j.ijrobp.2010.02.021
dc.identifier.endpage741en_US
dc.identifier.issn0360-3016
dc.identifier.issue3en_US
dc.identifier.pmid20646846en_US
dc.identifier.scopus2-s2.0-79957546454en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage735en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijrobp.2010.02.021
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19096
dc.identifier.volume80en_US
dc.identifier.wosWOS:000291711700014en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofInternational Journal Of Radiation Oncology Biology Physicsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiochemical Failureen_US
dc.subjectBounceen_US
dc.subjectBrachytherapyen_US
dc.subjectProstate Canceren_US
dc.subjectPSAen_US
dc.subjectExternal-Beam Radiationen_US
dc.subjectAntigen Bounceen_US
dc.subjectSeed Implantationen_US
dc.subjectRecommendationsen_US
dc.subjectRadiotherapyen_US
dc.subjectKineticsen_US
dc.subjectTherapyen_US
dc.titlePSA BOUNCE AND BIOCHEMICAL FAILURE AFTER BRACHYTHERAPY FOR PROSTATE CANCER: A STUDY OF 820 PATIENTS WITH A MINIMUM OF 3 YEARS OF FOLLOW-UPen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu